Shankar Siva, Radiation Oncologist at the Peter MacCallum Cancer Centre, shared a post on X:
“New European Urology Oncology Pooled trials Peter Mac Cancer Centre/UT MD Anderson shows adding Pembrolizumab to MDT for oligometastatic kidney cancer PFS (28 vs 17 mo; HR 0.57), esp. after prior therapy. Correlative data confirm MDT+ICI-evoked immune activation”
Chad Tang, Radiation Oncologist at the MD Anderson Cancer Center, shared a post by Shankar Siva on X, adding:
“Amazing collaboration with Shankar Siva, spearheaded by Alex Sherry. Improved pfs with pembro after MDT and improved immune activation. This is being tested now in the prospective randomized ASTROs study.”
Title: Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials
Authors: Alexander Sherry, Van To, Criselle D’souza, Simin Kiany, Niko Thio, Suyu Liu, Xiaowen Sun, Becky Castle, Sean Macdonald, Haesun Choi, Aaron Seo, Kieko Hara, David Pryor, Arun Azad, Ben Tran, Lewis Au, Lavinia Spain, Ethan Ludmir, Eric Jonasch, Nizar Tannir, Shankar Siva
Read the article: here.
Other articles featuring Shankar Siva on OncoDaily.
